別品名 |
STI-571, Gleevec, methanesulfonic acid; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
|
別包装 |
あり
|
純度 |
>=98%
|
分子量 |
589.718
|
CAS RN® |
220127-57-1
|
化合物の概要 |
Abl, c-Kit, PDGFR inhibitor.
|
構造 |
C30H35N7O4S
|
溶媒 |
Ethanol (0.2 mg/ml), DMSO (10 mg/ml), Dimethyl Formamide, PBS (2 mg/mL)
|
使用目的 |
Imatinib is an anticancer chemotherapeutic compound that inhibits Abl, c-Kit, and PDGFR; it is used clinically to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL). In cellular assays, imatinib accelerates erythroblast differentiation and inhibits melanogenesis.
|
その他 |
[融点]226C
|
参考文献 |
Wang Y, Zhao Y, Liu L, et al. Inhibitory effects of imatinib mesylate on human epidermal melanocytes. Clin Exp Dermatol. 2014 Mar;39(2):202-8. PMID: 24479586.D'allard D, Gay J, Descarpentries C, et al. Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket. PLoS One. 2013 Apr 23;8(4):e60961. PMID: 23637779.Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003 Feb;4(2):75-85. PMID: 12573349.
|
※サムネイル画像をクリックすると拡大画像が表示されます。
|
|
|
メーカー |
品番 |
包装 |
LKT
|
I4802
|
100 MG
|
※表示価格について
当社在庫 |
なし
|
納期目安 |
1週間程度
|
保存温度 |
常温
|
|